8-KRegulation FDExhibits & Filings

MCKESSON CORP 8-K Report, Regulation FD Disclosure (Oct 24, 2013)

Filed October 24, 2013For Securities:MCK

Summary

McKesson Corporation (MCK) announced a significant strategic move through a joint press release with Celesio AG on October 23, 2013. The company entered into an agreement to acquire a majority stake in Celesio, a global pharmaceutical wholesaler and retailer. This acquisition is coupled with parallel voluntary public tender offers for the remaining publicly traded shares and outstanding convertible bonds of Celesio. This transaction represents a substantial expansion of McKesson's international presence and capabilities, particularly in Europe. The primary focus for investors is the potential for significant growth and market share expansion driven by this acquisition. Investors should consider the strategic rationale behind acquiring Celesio, which likely involves increased scale, diversification, and synergies. The tender offer structure suggests McKesson is aiming for full control or a substantial integration of Celesio's operations, which could lead to enhanced profitability and a stronger competitive position in the global pharmaceutical distribution landscape.

Key Highlights

  • 1McKesson Corporation is acquiring a majority stake in Celesio AG.
  • 2McKesson will also launch voluntary public tender offers for the remaining shares and convertible bonds of Celesio.
  • 3The announcement was made via a joint press release with Celesio AG on October 23, 2013.
  • 4This transaction signifies a major international expansion for McKesson.
  • 5The acquisition is expected to enhance McKesson's global reach and market position.
  • 6The filing is an 8-K, indicating a material event for the company.
  • 7The information is furnished under Regulation FD Disclosure.

Frequently Asked Questions

The main purpose of this 8-K filing is to disclose McKesson Corporation's agreement to acquire a majority stake in Celesio AG and its intention to launch tender offers for the remaining shares and convertible bonds of Celesio. This is a significant corporate event.

Celesio AG is a global pharmaceutical wholesaler and retailer, and its acquisition by McKesson is expected to significantly expand McKesson's international operations, particularly in Europe.

It means McKesson is making an offer to all shareholders and bondholders of Celesio to buy their shares or bonds at a specified price, with the goal of acquiring the remaining publicly traded portions of the company beyond the initial majority stake.

Potential benefits include increased scale of operations, expanded geographic reach (especially in Europe), diversification of revenue streams, potential cost synergies, and a stronger competitive position in the global pharmaceutical distribution market.